PROFOUND MEDICAL CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.06 CAD | +0.50% |
|
-7.20% | -9.37% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 174.8 | 514 | 296.2 | 302.3 | 266.8 | 245.8 | - | - |
| Enterprise Value (EV) 1 | 174.8 | 514 | 296.2 | 302.3 | 242.2 | 232 | 287.1 | 320.6 |
| P/E ratio | -8.1 x | -16.6 x | -7.5 x | -7.64 x | -6.11 x | -6.45 x | -7.16 x | -16.9 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 31.6 x | 55.8 x | 34 x | 32.9 x | 27.5 x | 15.4 x | 5.62 x | 3.36 x |
| EV / Revenue | 31.6 x | 55.8 x | 34 x | 32.9 x | 25 x | 14.5 x | 6.57 x | 4.38 x |
| EV / EBITDA | -9.85 x | -23.5 x | -11 x | -9.26 x | -7.48 x | -6.73 x | -11.2 x | -77.7 x |
| EV / FCF | -8.73 x | -19.8 x | -10.4 x | -8.53 x | -8.07 x | -5.91 x | -6.82 x | -7.64 x |
| FCF Yield | -11.5% | -5.05% | -9.59% | -11.7% | -12.4% | -16.9% | -14.7% | -13.1% |
| Price to Book | 9.37 x | 3.69 x | - | 4.21 x | 5.65 x | 7.32 x | 14.4 x | 31.1 x |
| Nbr of stocks (in thousands) | 11,853 | 19,626 | 20,769 | 20,876 | 24,033 | 24,429 | - | - |
| Reference price 2 | 14.75 | 26.19 | 14.26 | 14.48 | 11.10 | 10.06 | 10.06 | 10.06 |
| Announcement Date | 20-03-03 | 21-03-02 | 22-03-03 | 23-03-07 | 24-03-07 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5.528 | 9.217 | 8.714 | 9.178 | 9.694 | 15.95 | 43.69 | 73.16 |
| EBITDA 1 | -17.75 | -21.86 | -26.89 | -32.64 | -32.39 | -34.45 | -25.65 | -4.127 |
| EBIT 1 | -19.77 | -23.8 | -38.41 | -40.67 | -38.53 | -38.6 | -31.82 | -7.48 |
| Operating Margin | -357.63% | -258.26% | -440.72% | -443.08% | -397.5% | -241.96% | -72.83% | -10.22% |
| Earnings before Tax (EBT) 1 | -20 | -27.23 | -38.79 | -38.99 | -38.64 | -39.27 | -36.01 | -15.88 |
| Net income 1 | -20.19 | -27.29 | -38.92 | -39.39 | -38.47 | -38.38 | -30.34 | -16.12 |
| Net margin | -365.3% | -296.03% | -446.66% | -429.11% | -396.85% | -240.58% | -69.44% | -22.03% |
| EPS 2 | -1.820 | -1.577 | -1.902 | -1.896 | -1.818 | -1.559 | -1.404 | -0.5946 |
| Free Cash Flow 1 | -20.03 | -25.96 | -28.39 | -35.44 | -30.02 | -39.26 | -42.12 | -41.98 |
| FCF margin | -362.37% | -281.68% | -325.8% | -386.17% | -309.72% | -246.09% | -96.39% | -57.38% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 20-03-03 | 21-03-02 | 22-03-03 | 23-03-07 | 24-03-07 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3.16 | 1.265 | 1.772 | 2.603 | 2.796 | 1.727 | 2.486 | 2.154 | 2.383 | 2.705 | 3.395 | 3.914 | 4.131 | 4.573 | 12.52 |
| EBITDA 1 | -8.974 | -8.646 | -7.79 | -7.315 | -9.142 | -9.376 | -7.504 | -7.15 | -7.649 | -10.2 | -8.573 | -8.752 | -8.842 | -9.605 | -7.675 |
| EBIT 1 | -9.476 | -12.33 | -9.471 | -9.999 | -11.31 | -8.652 | -9.14 | -8.655 | -9.047 | -11.83 | -9.425 | -9.454 | -9.44 | -9.864 | -9.56 |
| Operating Margin | -299.84% | -974.75% | -534.6% | -384.1% | -404.62% | -501.04% | -367.63% | -401.75% | -379.63% | -437.13% | -277.66% | -241.56% | -228.52% | -215.68% | -76.34% |
| Earnings before Tax (EBT) 1 | -7.404 | -12.92 | -10.63 | -7.603 | -6.818 | -12.81 | -8.947 | -9.843 | -7.649 | -12.3 | -9.47 | -9.56 | -9.605 | -10.32 | -9.56 |
| Net income 1 | -7.469 | -12.88 | -10.67 | -7.623 | -6.864 | -13.09 | -9.074 | -9.89 | -7.673 | -12 | -9.515 | -9.65 | -9.695 | -10.41 | -9.56 |
| Net margin | -236.34% | -1,018.14% | -602.27% | -292.84% | -245.55% | -757.92% | -364.95% | -459.11% | -321.99% | -443.45% | -280.31% | -246.56% | -234.7% | -227.69% | -76.34% |
| EPS 2 | -0.3612 | -0.6213 | -0.5195 | -0.3600 | -0.3297 | -0.6319 | -0.4277 | -0.4706 | -0.3586 | -0.5655 | -0.4127 | -0.4040 | -0.4083 | -0.4310 | -0.3900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 21-11-04 | 22-03-03 | 22-05-09 | 22-08-04 | 22-11-03 | 23-03-07 | 23-05-10 | 23-08-09 | 23-11-02 | 24-03-07 | - | - | - | - | - |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | 41.3 | 74.9 |
| Net Cash position 1 | - | - | - | - | 24.6 | 13.7 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | -1.612 x | -18.14 x |
| Free Cash Flow 1 | -20 | -26 | -28.4 | -35.4 | -30 | -39.3 | -42.1 | -42 |
| ROE (net income / shareholders' equity) | -89.2% | -38.7% | - | -43.2% | -68.7% | -110% | -96% | -117% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 1.570 | 7.100 | - | 3.440 | 1.960 | 1.370 | 0.7000 | 0.3200 |
| Cash Flow per Share 2 | -1.800 | -1.500 | - | -1.710 | -1.420 | -0.3400 | -0.6900 | -0.1800 |
| Capex 1 | - | - | 0.04 | - | - | - | - | - |
| Capex / Sales | - | - | 0.47% | - | - | - | - | - |
| Announcement Date | 20-03-03 | 21-03-02 | 22-03-03 | 23-03-07 | 24-03-07 | - | - | - |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
10.06
CAD
Average target price
12.5
CAD
Spread / Average Target
+24.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.37% | 180M | |
| +7.84% | 218B | |
| +7.35% | 184B | |
| +13.04% | 135B | |
| -1.33% | 62.38B | |
| +11.80% | 51.37B | |
| +4.81% | 50.9B | |
| +0.30% | 40.87B | |
| +2.78% | 36.28B | |
| +26.14% | 31.88B |
- Stock Market
- Equities
- PRN Stock
- Financials Profound Medical Corp.